Milan-based StarTric, a medtech startup, announced on Monday that it has secured funding in a new seed financing round from early-stage investors, including NLC Health Impact Fund, Growth Engine, and Business Angels.The company will use the funds to advance its next-generation technology for the transcatheter repair of the tricuspid heart valve, addressing a critical need in cardiac care.“The funds from this round will be used to finalise the design of a minimally invasive device that is aimed at treating TR with unprecedented efficacy, ability to be “personalised” to each patient, and ease of use. This milestone is of the utmost importance, as its achievement will pave the way to the production of the investigational device for the first-in-human trial”, says Daniele Zanotti, CEO of StarTric.What is Tricuspid Regurgitation (TR)?Tricuspid regurgitation (TR) is a serious heart condition that affects millions of people worldwide.It is the leakage of blood backward through the tricuspid valve each time the right ventricle contracts.However, it currently lacks effective and accessible treatment options.- A message from our partner -And here’s where StarTric comes into play!StarTric: Transforming tricuspid regurgitation treatmentStarTric develops a minimally invasive device addressing Tricuspid Regurgitation (TR).The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique developed by the founders Prof. Ottavio Alfieri and Prof.Michele De Bonis.As a result, it could significantly improve patient outcomes and reduce recovery times.“We have achieved several key development milestones and received significant interest and appreciation within the interventional cardiology community at the recent EuroPCR conference. We are also very glad with the vote of confidence of our investors and the intense teamwork with our clinical partners to accelerate the company towards clinical use,” says Eugenio Passanante, founder and CFO.The investorThe NLC Health Impact Fund is established to drive investments in early-stage innovations in healthcare.The fund deploys capital towards ventures of varied maturity levels, providing initial and follow-on funding.With the NLC Health Impact Fund, NLC provides investors with the opportunity to access a diversified portfolio of impactful healthtech ventures.“StarTric’s technology is setting a new standard in the ability to treat tricuspid valve regurgitation, reducing the need for invasive surgeries while reproducing their clinical efficacy, thus lowering healthcare costs and improving patient care. We are excited to support StarTric as they progress towards the first-in-human trial and look forward to broad clinical adoption of this groundbreaking technology,” says Alessandro Radaelli, Venture Partner at NLC Health Ventures

Amsterdam-based NLC Health Ventures, in collaboration with Verily (an Alphabet Inc. company formerly known as Google LifeSciences), on Monday announced the launch of Exolvo Biosciences, a biotech company delivering solutions for biologic drug delivery.Through Exolvo, NLC seeks to advance drug delivery technology that was incubated within Verily and is now being spun out as a stand-alone private early-stage venture under NLC.Exolvo’s oral drug delivery technology is distinguished by its flexible capsule size and modular design, allowing adaptation to a variety of large molecular structures.“This technology has tremendous potential for significant impact. For patients, it means an improved and better treatment experience, and for healthcare workers, it simplifies administration and enhances efficiency in delivering care,” says Nick Ibery, UK Lead Partner at NLC.The Need for Exolvo BiosciencesBiologic drugs are critical for treating chronic conditions, but their size and complexity make oral delivery challenging.As a result, biologic drugs are usually administered through frequent and painful needle injections or intravenous administration.- A message from our partner -Such treatments can be burdensome for patients and costly for healthcare systems.“Talk to anyone living with a chronic disease like diabetes and they will mention the struggle of having to inject themselves – in some cases – even multiple times a day. There is a need for innovative solutions that can make treatments more accessible and less invasive for people that live with chronic conditions,“ says Exolvo co-founder and CEO, Brian Longstreet.Exolvo Biosciences is a biotech company that aims to transform the oral delivery of large, complex molecules.Using Verily’s technology, Exolvo aims to transform biological drug delivery to make treatments more accessible and less invasive.Exolvo’s technology is making progress towards assembling an IND (Investigational New Drug) package in the U.S. while simultaneously actively engaging with key pharmaceutical and biotech partners.NLC Health Ventures: Active health technology investorBased out of Amsterdam, NLC Health Ventures is the most active health technology investor in Europe and the world’s largest healthtech venture builder.NLC finds, builds, and scales transformative health innovations to provide more patients with quality care.NLC is ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17.With more than 100 startups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale.The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s startups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding

Amsterdam-based NLC Health Ventures, in collaboration with Verily (an Alphabet Inc. company formerly known as Google LifeSciences), on Monday announced the launch of Exolvo Biosciences, a biotech company delivering solutions for biologic drug delivery.Through Exolvo, NLC seeks to advance drug delivery technology that was incubated within Verily and is now being spun out as a stand-alone private early-stage venture under NLC.Exolvo’s oral drug delivery technology is distinguished by its flexible capsule size and modular design, allowing adaptation to a variety of large molecular structures.“This technology has tremendous potential for significant impact. For patients, it means an improved and better treatment experience, and for healthcare workers, it simplifies administration and enhances efficiency in delivering care,” says Nick Ibery, UK Lead Partner at NLC.The Need for Exolvo BiosciencesBiologic drugs are critical for treating chronic conditions, but their size and complexity make oral delivery challenging.As a result, biologic drugs are usually administered through frequent and painful needle injections or intravenous administration.- A message from our partner -Such treatments can be burdensome for patients and costly for healthcare systems.“Talk to anyone living with a chronic disease like diabetes and they will mention the struggle of having to inject themselves – in some cases – even multiple times a day. There is a need for innovative solutions that can make treatments more accessible and less invasive for people that live with chronic conditions,“ says Exolvo co-founder and CEO, Brian Longstreet.Exolvo Biosciences is a biotech company that aims to transform the oral delivery of large, complex molecules.Using Verily’s technology, Exolvo aims to transform biological drug delivery to make treatments more accessible and less invasive.Exolvo’s technology is making progress towards assembling an IND (Investigational New Drug) package in the U.S. while simultaneously actively engaging with key pharmaceutical and biotech partners.NLC Health Ventures: Active health technology investorBased out of Amsterdam, NLC Health Ventures is the most active health technology investor in Europe and the world’s largest healthtech venture builder.NLC finds, builds, and scales transformative health innovations to provide more patients with quality care.NLC is ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17.With more than 100 startups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale.The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s startups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding